ClinicalTrials.gg
RecruitingNCT07006298GOLDENEYEUpdated Jun 8, 2025

One-year Outcomes by Index Treatment in Elderly Patients With Acute Cholecystitis

An observational study in Acute Cholecystitis, sponsored by Instituto de Investigación Sanitaria y Biomédica de Alicante. Recruiting at 1 site in Spain. Open to participants aged 70 Years and older. Per ClinicalTrials.gov, last updated 2025-06-08.

Sponsored by Instituto de Investigación Sanitaria y Biomédica de Alicante · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
376
Ages
70 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Cholecystitis, Acute with a site in Spain — 7 open to participants now, 7 under way, none of them phase 3. Cholecystitis, Acute · Spain.

Started
2025
with 1 other
Observational
5 of 13
1 open now
Registered
11th of 13
by date

Among the 13 studies in Cholecystitis, Acute with a site in Spain, this one is one of 2 that started in 2025, is one of 5 observational ones, and was the 11th registered.

Cholecystitis, Acute

140 studies on the registry are indexed under Cholecystitis, Acute; 30 are open to participants now.

Browse Cholecystitis, Acute studies →

Open to participants now

7 of the 13 studies in Cholecystitis, Acute with a site in Spain are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →

Who these studies take

Of the 21 Cholecystitis, Acute studies recruiting now, 17 (81%) set no upper age limit and 2 (10%) stop at 75 or younger; 2 take children under 18; none take healthy volunteers.

This study: 70 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Cholecystitis, Acute with a site in Spain, or all of them as a file.
02

Study summary

Background: The GOLDENEYE study is an international, multicenter, prospective observational investigation designed to compare the outcomes of various management strategies for acute cholecystitis in patients aged 70 years and older. This research is driven by the increasing prevalence of gallstones and biliary tract diseases in the elderly, alongside a recognition that the burden of comorbidity in this population may necessitate tailored treatment approaches to optimize outcomes.

Patients and Methods: The primary aims of the study are to evaluate the efficacy of different treatments -supportive care, percutaneous gallbladder drainage, early or delayed cholecystectomy, and EUS-guided gallbladder drainage- on patient-centric outcomes, including one-year additional treatment modalities, hospital readmissions, outpatient encounters, quality of life, and survival rates. The study adopts a robust design incorporating propensity score matching analysis to account for the non-randomized allocation of treatment modalities, thereby minimizing selection bias and enhancing the comparability of treatment groups. Inclusion criteria are centered on patients ≥70 years diagnosed with acute cholecystitis, as per the Tokyo guidelines, while key exclusion criteria include prior episodes of cholecystitis or pancreatitis, terminal illness, and concurrent diagnosis of acute pancreatitis, cholangitis, bile duct disease, or digestive malignancy. Data collection will leverage the REDCap platform for systematic and secure data management, facilitating real-time data entry and monitoring across participating centers.

Discussion: This comprehensive approach ensures the integrity and reliability of data collected on demographics, gender, clinical outcomes, and quality of life measures. Through its innovative design and methodology, the GOLDENEYE study aims to generate evidence-based insights that will significantly influence the management of acute cholecystitis in the elderly, ultimately improving patient outcomes and healthcare practices in this growing demographic population.

03

Conditions studied

  • Acute Cholecystitis

Browse trials for

Keywords

  • laparoscopic cholecystectomy
  • Conservative Treatment
  • drainage
  • Endosonography
  • Propensity Score
  • Retrospective Studies
04

Who can participate

Ages eligible
70 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients ≥70 years diagnosed with acute cholecystitis, as per the Tokyo guidelines

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • patients ≥70 years
  • diagnosed with acute cholecystitis, as per the Tokyo guidelines

Exclusion criteria

Exclusion Criteria:

  • prior episodes of cholecystitis or pancreatitis
  • terminal illness
  • concurrent diagnosis of acute pancreatitis, cholangitis, bile duct disease, or digestive
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
376 participants (estimated)
Patient registry
No

Groups and cohorts

  • Supportive care

    Patients that received antibiotics only

  • Cholecystectomy

    Patients that undergo early or delayed cholecystectomy

  • percutaneous gallbladder drainage

    Patients that undergo percutaneous gallbladder drainage

  • EUS-guided gallbladder drainage

    Patients that undergo EUS-guided gallbladder drainage

06

What researchers measure

Primary outcomes

  1. 1 year additional procedures, hospital readmissions or outpatient visits

    Percentage of patients requiring any additional procedure, hospital readmission or outpatient visit during the first year.

    Time frame: 1 year

Secondary outcomes

  1. 1-year health-related quality of life

    The EQ-5D-5L questionnaire is used to assess quality of life in elderly individuals. It encompasses five key dimensions: mobility, self-care, usual activities, pain/discomfort, and anxiety/depression. Each dimension is evaluated across five severity levels. Level 1 indicates that the patient has no problems. Level 5 indicates the worst condition. Additionally, the questionnaire has a scale. This scale is numbered from 0 to 100. A score of 100 indicates the best health possible. Zero means the worst health possible. Measurements will be obtained during the initial admission and at one, three, and twelve months.

    Time frame: 1 year

  2. 1-year overall survival

    Survival will be defined as the time elapsed between the date of index admission and the date of death or last follow-up. Survival curves will be constructed by the Kaplan-Meier method and compared using the log-rank test. A multivariable Cox proportional hazards regression model will be used to identify prognostic factors associated with survival. All variables that are significant at 0.10 in the univariable analysis will be entered into a multivariable model. P-values less than 0.05 will be considered statistically significant. All analyses will be performed with RStudio, version 1.2.5001 (Integrated Development for R. RStudio, Inc., Boston, MA, USA).

    Time frame: 1 year

07

Study locations

1 of 1 sites recruiting
  • Instituto de Investigación Sanitaria y Biomédica de Alicante (ISABIAL)
    Alicante, 03010, Spain
    Recruiting
    • Felix Lluis, MD, PhD · Contactgoldeneye@isabial.es · +34 601-023-068
    • Felix Lluis, MD, PhD · Principal investigator
08

References and documents

Related links

Individual participant data

Plan to share: No — The Steering Committee and statistical advisors will have access to the final dataset. Members of the GOLDENEYE study that recruited patients may claim access to the final dataset to perform ancillary studies; the Steering Committee will study these proposals. Any data required to support the protocol can be supplied on request.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for May 2027, 24 months after the start.

Of 22 observational studies under Cholecystitis, Acute, half reached primary completion within 20 months of starting (the median), counting those still running; a quarter within 11 and three quarters within 42. This study's planned 24 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
May 14, 2025
First posted
Jun 5, 2025
StartActual
May 15, 2025
Primary completionEst.
May 15, 2027
CompletionEst.
May 15, 2027
Last update
Jun 8, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 8, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07006298
Lead sponsor
Instituto de Investigación Sanitaria y Biomédica de Alicante
Responsible party
Nuria Lluis Viñas (MD, PhD, Instituto de Investigación Sanitaria y Biomédica de Alicante) — Principal investigator
First posted
Jun 5, 2025
Start date
May 15, 2025
Primary completion
May 15, 2027 (estimated)
Completion
May 15, 2027 (estimated)
Last update
Jun 8, 2025

Study contacts

Nuria Lluis, MD, PhD
Contact
nuria.lluis@pennmedicine.upenn.edu
+1 (215) 662-4000

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion